BAYER shares: analysis, forecast & outlook for financial experts

BAYER shares: analysis, forecast & outlook for financial experts

According to a report by stock3.com, Bayer AG is facing major challenges. The company's share price has fallen sharply, particularly due to the glyphosate litigation and the group's austerity measures.

The glyphosate litigation has already placed significant financial burdens on Bayer and is expected to result in additional costs. To date, the company has already paid out more than $10 billion in damages and has around 40,000 lawsuits still pending. This uncertainty weighs on the share price and leads to massive selling pressure.

In addition, Bayer plans to save around 6 billion euros by 2026, especially in the pharmaceutical sector. This could have a negative impact on the company's research and development activities.

From a chart perspective, Bayer shares are in a clear downward trend and there are no signs of bottoming out. The share price recently broke an important support at EUR 48, which could lead to another wave of selling.

However, there is currently a small support in the market at EUR 32.69, which could potentially lead to a short-term countermove. Nevertheless, the environment is only slightly interesting for active traders who trade short-term.

Overall, the current situation is extremely challenging for Bayer, and it remains to be seen how the glyphosate litigation and austerity measures will impact the company in the long term. The financial industry will therefore closely monitor developments at Bayer and may have to adapt its investment strategies.